EyePoint names Tarek Hassan chief strategic science officer

EyePoint, Inc.

EyePoint, Inc.

EYPT

0.00
  • EyePoint named Tarek S. Hassan as senior vice president, chief strategic science officer, reporting to CEO Jay S. Duker.
  • Role targets strategy across the portfolio, including lead program DURAVYU, as Phase 3 wet AMD topline data nears.
  • Hassan is a retina specialist with 35+ years’ experience, now a professor at Oakland University William Beaumont School of Medicine.
  • He is also a senior partner at Associated Retinal Consultants, with experience across 180+ multicenter clinical trials.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EyePoint Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607130700PRIMZONEFULLFEED9760599) on July 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.